Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 100 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphoma :venclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemia :venclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 50 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphoma :venclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemia :venclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 50 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphoma :venclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemia :venclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - 11677 - enteral feeding kit - the abbvie j is intended to provide long-term enteral access for administration of medication to the small intestine. the abbvie j is indicated for the administration of the medication duodopa (levodopa/carbidopa) intestinal gel.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - 16798 - tube, feeding, nasoenteral - the abbvie nj is intended to provide short-term enteral access for the administration of medicine to the small intestine. the abbvie nj is indicated for the administration of the medication duodopa (levodopa/carbidopa intestinal gel).

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - tablets prolonged release - upadacitinib as hemihydrate 45 mg - upadacitinib - ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

United States - English - NLM (National Library of Medicine)

abbvie inc. - upadacitinib (unii: 4ra0kn46e0) (upadacitinib - unii:4ra0kn46e0) - rinvoq® is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers.  ● limitations of use: rinvoq is not recommended for use in combination with other jak inhibitors, biologic disease-modifying antirheumatic drugs (dmards), or with potent immunosuppressants such as azathioprine and cyclosporine. rinvoq is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers. ● limitations of use: rinvoq is not recommended for use in combination with other jak inhibitors, biologic dmards, or with potent immunosuppressants such as azathioprine and cyclosporine. rinvoq is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - elagolix as sodium - film coated tablets - elagolix as sodium 150 mg - elagolix - orilissa is indicated for the management of moderate to severe pain associated with endometriosis.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - elagolix as sodium - film coated tablets - elagolix as sodium 200 mg - elagolix - orilissa is indicated for the management of moderate to severe pain associated with endometriosis.

United States - English - NLM (National Library of Medicine)

abbvie inc. - ombitasvir heminonahydrate (unii: eqe3i70j3w) (ombitasvir - unii:2302768xj8), paritaprevir dihydrate (unii: hrq5901o78) (paritaprevir - unii:ou2ym37k86), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - ombitasvir 12.5 mg - viekira pak is indicated for the treatment of adult patients with chronic hepatitis c virus (hcv) [see dosage and administration ( 2.2 ) and clinical studies ( 14 )] : - genotype 1b without cirrhosis or with compensated cirrhosis - genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin. - if viekira pak is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin. - viekira pak is contraindicated: ○ in patients with moderate to severe hepatic impairment (child-pugh b and c) due to risk of potential toxicity [see warnings and precautions ( 5.2 ), use in specific populations ( 8.6 ) and clinical pharmacology ( 12.3 )] . ○ with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see drug interactions ( 7 ) and clinical pharm